NCT03732859 (PROOF-NEXT) is a clinical trial in Idiopathic Pulmonary Fibrosis, sponsored by Belgian Thoracic Society.

Who is sponsoring NCT03732859?

NCT03732859 is sponsored by Belgian Thoracic Society.

What condition does NCT03732859 study?

NCT03732859 studies Idiopathic Pulmonary Fibrosis.

Is NCT03732859 still recruiting?

NCT03732859 is currently completed. Last updated 15 February 2022.

Last reviewed 2022-02-15 · How we verify

NCT03732859: PROOF-NEXT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PROOF-Registry New and Extended Belgium -Luxembourg

Completed Last updated 15 February 2022

What this trial tests

trial in Idiopathic Pulmonary Fibrosis in 575 participants. Completed in 9 January 2022.

Timeline

9 January 2018

Primary endpoint
1 November 2021

9 January 2022

Quick facts

Lead sponsor	Belgian Thoracic Society
Status	Completed
Study type	OBSERVATIONAL
Enrollment	575
Start date	9 January 2018
Primary completion	1 November 2021
Estimated completion	9 January 2022
Sites	9 locations across Belgium, Luxembourg

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Belgian Thoracic Society

Who can join

19 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Patient Registries in Idiopathic Pulmonary Fibrosis.
Culver DA, Behr J, Belperio JA, Corte TJ, et al · · 2019 · cited 39× · PMID 31034241 · DOI 10.1164/rccm.201902-0431ci

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03732859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Belgian Thoracic Society
Last refreshed: 15 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing